Mallinckrodt and Endo Announce Significant Progress in Proposed Merger Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.

#MNK #NDOI Mallinckrodt and Endo Announce Significant Progress in Proposed Merger

www.stocktitan.net/news/MNK/mallinckrodt-an...

Major Pharma Merger: Mallinckrodt-Endo Deal Creates $3.6B Revenue Giant with $150M Synergies Strategic merger combines 17 manufacturing facilities, targets $150M synergies, and positions new pharma leader for growth with projected $1.2B EBITDA by 2025.

#MNK #NDOI Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader

www.stocktitan.net/news/MNK/mallinckrodt-an...